Literature DB >> 8359051

Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.

H J Stein1, J R Siewert.   

Abstract

Barrett's esophagus (i.e. columnar epithelial metaplasia in the distal esophagus) is an acquired condition that in most patients results from chronic gastroesophageal reflux. It is a disorder of the white male in the Western world with a prevalence of about 1/400 population. Due to the decreased sensitivity of the columnar epithelium to symptoms, Barrett's esophagus remains undiagnosed in the majority of patients. Gastroesophageal reflux disease in patients with Barrett's esophagus has a more severe character and is more frequently associated with complications as compared with reflux patients without columnar mucosa. This appears to be due to a combination of a mechanically defective lower esophageal sphincter, inefficient esophageal clearance function, and gastric acid hypersecretion. Excessive reflux of alkaline duodenal contents may be responsible for the development of complications (i.e., stricture, ulcer, and dysplasia). Therapy of benign Barrett's esophagus is directed towards treatment of the underlying reflux disease. Barrett's esophagus is associated with a 30- to 125-fold increased risk for adenocarcinoma of the esophagus. The reasons for the dramatic rise in the incidence of esophageal adenocarcinoma, which occurred during the past years, are unknown. High grade dysplasia in a patient with columnar mucosa is an ominous sign for malignant degeneration. Whether an esophagectomy should be performed in patients with high grade dysplasia remains controversial. Complete resection of the tumor and its lymphatic drainage is the procedure of choice in all patients with a resectable carcinoma who are fit for surgery. In patients with tumors located in the distal esophagus, this can be achieved by a transhiatal en-bloc esophagectomy and proximal gastrectomy. Early adenocarcinoma can be cured by this approach. The value of multimodality therapy in patients with advanced tumors needs to be shown in randomized prospective trials.

Entities:  

Mesh:

Year:  1993        PMID: 8359051     DOI: 10.1007/bf01354551

Source DB:  PubMed          Journal:  Dysphagia        ISSN: 0179-051X            Impact factor:   3.438


  118 in total

1.  Circadian esophageal motor function in patients with gastroesophageal reflux disease.

Authors:  H J Stein; E P Eypasch; T R DeMeester; T C Smyrk; S E Attwood
Journal:  Surgery       Date:  1990-10       Impact factor: 3.982

2.  Characteristics of the columnar-cell lined (Barrett's) esophagus.

Authors:  E J Burbige; J J Radigan
Journal:  Gastrointest Endosc       Date:  1979-11       Impact factor: 9.427

3.  Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux.

Authors:  H J Stein; A P Barlow; T R DeMeester; R A Hinder
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

4.  Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia.

Authors:  R J Kalish; P E Clancy; M B Orringer; H D Appelman
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

5.  Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group.

Authors:  S J Spechler
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

6.  Adenocarcinoma in Barrett's oesophagus: an overrated risk.

Authors:  A H Van der Veen; J Dees; J D Blankensteijn; M Van Blankenstein
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

7.  Barrett's oesophagus: effect of antireflux surgery on symptom control and development of complications.

Authors:  S E Attwood; A P Barlow; T L Norris; A Watson
Journal:  Br J Surg       Date:  1992-10       Impact factor: 6.939

8.  High-grade dysplasia in the columnar-lined esophagus.

Authors:  N K Altorki; M Sunagawa; A G Little; D B Skinner
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

9.  Histopathologic characteristics of early adenocarcinoma in Barrett's esophagus.

Authors:  T Nishimaki; A H Hölscher; M Schüler; E Bollschweiler; K Becker; J R Siewert
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

10.  Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  J J Thompson; K R Zinsser; H T Enterline
Journal:  Hum Pathol       Date:  1983-01       Impact factor: 3.466

View more
  24 in total

1.  A scintigraphic study of local oesophageal bolus transit: differences between patients with Barrett's oesophagus and healthy controls.

Authors:  A W Stier; H J Stein; H-D Allescher; M Feith; M Schwaiger
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Antagonist: endoscopic surveillance of patients with Barrett's oesophagus.

Authors:  R J Playford
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

3.  Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center.

Authors:  Shayan Irani; Henry P Parkman; Rebecca Thomas; Benjamin Krevsky; Robert S Fisher; Peter Axelrod
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

4.  Era of Barrett's surveillance: does equipment matter?

Authors:  Jayan Mannath; Krish Ragunath
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

5.  Endoscopic resection of two rare esophageal tumors.

Authors:  Hanne Ooms; Paul A Pelckmans; Steven Van Outryve; Ann Driessen; Tom G Moreels
Journal:  J Gastrointest Cancer       Date:  2015-06

6.  Achalasia: a risk factor that must not be forgotten for esophageal squamous cell carcinoma.

Authors:  Shareni Ríos-Galvez; Arturo Meixueiro-Daza; Jose Maria Remes-Troche
Journal:  BMJ Case Rep       Date:  2015-01-06

7.  Prevalence of Barrett's esophagus in Hispanics is similar to Caucasians.

Authors:  K Bersentes; R Fass; S Padda; C Johnson; R E Sampliner
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

Review 8.  Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction.

Authors:  Manuel Pera
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

9.  Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo.

Authors:  Elena Piazuelo; Paula Esquivias; Alba De Martino; Carmelo Cebrián; Blanca Conde; Sonia Santander; Sonia Emperador; María Asunción García-González; Patricia Carrera-Lasfuentes; Angel Lanas
Journal:  Dig Dis Sci       Date:  2016-06-24       Impact factor: 3.199

10.  Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.

Authors:  H J Stein; W K Kauer; H Feussner; J R Siewert
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.